<DOC>
	<DOCNO>NCT00697866</DOCNO>
	<brief_summary>The purpose present study evaluate immunogenicity safety three consecutive production lot novel adjuvanted HBV vaccine . The safety candidate vaccine assess use Engerix™-B control .</brief_summary>
	<brief_title>Consistency 3 Consecutive Lots Novel HBV Vaccine With Single-blind Safety Evaluation Using Engerix™-B Control</brief_title>
	<detailed_description>Double-blind identity consistency lot , single-blind control group/study vaccine identity . At time conduct study , sponsor GlaxoSmithKline know former name SmithKline Beecham</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male female , include , 15 50 year age time first vaccination . Written inform consent obtain subject/ parent guardian subject applicable Free obvious health problem establish medical history clinical examination enter study . If subject female , must nonchildbearing potential , , childbearing potential , must abstinent use adequate contraceptive precaution 30 day prior vaccination , negative pregnancy test must agree continue precaution two month completion vaccination series . Use investigational nonregistered drug vaccine study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Planned administration/Administration vaccine foreseen study protocol within 30 day first dose vaccine ( ) . Previous vaccination hepatitis B History nonresponse previous hepatitis B vaccination Known exposure hepatitis B within previous 6 week History hepatitis B infection Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . A family history congenital hereditary immunodeficiency . Suspected confirmed multiple sclerosis subject ( applicable Centre 5/France ) History allergic disease reaction likely exacerbate component vaccine . Acute disease time enrolment . Hepatomegaly , right upper quadrant abdominal pain tenderness . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period . Pregnant lactate female</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Adjuvanted hepatitis B vaccine</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>Recombinant hepatitis B vaccine</keyword>
</DOC>